Pilot Study To Assess The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
- Histopathologic evidence of well differentiated neuroendocrine tumor of
- Evidence of metastatic disease of at least 2.0 cm in the liver by MRI or CT imaging.
- Patient ≥18 years of age on the day of signing informed consent.
- Any contraindication to MRI based on departmental MR questionnaire
- Inability to cooperate for an MR exam
- Patient has a history of a second active malignancy with evidence of metastases.
Patients with a history of resected prior malignancy or one that would not interfere
with the MRI results is allowed.
- Patient has known psychiatric or substance abuse disorders that would, in the opinion
of the treating investigator, interfere with cooperation with the requirements of the
Type of Study:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
reproducibility of diffusion weighted imaging for neuroendocrine liver metastases.
The investigators will calculate an ADC value for each metastasis that was chosen through consensus by the two participating radiologists. ADC is a voxel-level measurement so summary measures will be employed in order to get a single measurement for the ROI of each metastasis under study. For both the clinical and research MRI, the investigators will take the voxel-level data and calculate the mean, median, and minimum ADC within each ROI.
Outcome Time Frame:
Richard Kinh Gian Do, MD,PhD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
- Gastro-enteropancreatic Neuroendocrine Tumor
- Secondary Malignant Neoplasm of Liver
- ADRENAL GLAND
- Liver Neoplasms
- Neoplasm Metastasis
- Neuroendocrine Tumors
- Neoplasms, Second Primary
- Intestinal Neoplasms
- Pancreatic Neoplasms
- Stomach Neoplasms
|Memorial Sloan Kettering Cancer Center||New York, New York 10021|